

Innovation all for the patients



Roche A member of the Roche group

Atea Announces Update and Topline Results of MOONSONG Study Evaluating AT-527 for COVID-19 in the Outpatient Setting

TOKYO, October 20, 2021 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Atea issued a press release on October 19 regarding update and topline results of MOONSONG study evaluating the RNA polymerase inhibitor AT-527 for COVID-19 in the outpatient setting.

Please refer to the link below for details of the press release:

Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting

<https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update-and-topline-results-phase-2>

###